Take on the city with adidas PureBOOST DPR, engineered to deliver a raw, real and adaptive street running experience

Signature BOOST technology with a new 8mm head-to-toe offset stores and unleashes energy more effectively
HERZOGENAURACH, GERMANY — Today adidas revealed its latest addition to the PureBOOST franchise that launched earlier this year. The new PureBOOST DPR is an  innovation engineered to take runners closer to the city streets. The shoe is made for those whose unafraid attitude makes no urban environment unconquerable. The new agile and adaptive design features the latest application of adidas’ industry leading BOOST technology, with a new 8mm heel-to-toe offset, that stores and unleashes energy more effectively every time it hits the ground, enabling runners to truly ‘feel’ the streets.

When developing PureBOOST DPR, adidas looked at the needs of the urban runner and designed a shoe that is as dynamic and adaptable as they are. PureBOOST DPR was created to support runners dodging traffic, racing street lights and weaving through pedestrians, working with the unpredictable surroundings and harnessing its energy.

“All over the world, runners are exploring cities and expressing their own creativity in the routes they choose and the challenges they take on." said Stephan Schneider, Product Manager at adidas Global Running. "We wanted to build something purely designed for this type of runner, and loved the idea of creating a more adaptive running experience. This led us to design an 8mm heel-to-offset, that when paired with signature BOOST technology allows the feet to sit lower, deeper, and much closer to the streets.”

The shoe’s key features include:

• One-piece engineered circular knit upper - Aramis-tested for a seamless and adaptive fit, wrapping the foot from the inside of the midfoot around to the outside. Providing comfort no matter the route or obstacle.
• Heel fit counter system - designed to enhance the support of the foot and the Achilles, while allowing the foot to move effortlessly with the shoe.
• Wider forefoot - providing a more stable platform that tailors itself in the pivotal moments of transition when running over various urban surfaces and around corners.
• Stretchweb outsole - enabling a smoother and more flexible ride, working in harmony with BOOST to unleash a runner’s full potential.
• BOOST - ultra-responsive comfort and cushioning that stores and returns energy every time the foot hits the ground.

The adidas PureBOOST DPR will be available late May 2017 at adidas.ca/PureBOOST.

Twitter: @adidasca
Instagram: @adidasca
#PureBOOST

New National Mental Health Coalition Seeks Equitable Access to Depression Medications

'An employment lottery should not be the basis for treating the most significant public health issue of the 21st century'

OTTAWA, May 3, 2017 /CNW/ - During CMHA's Mental Health Week, Canadians are being asked to 'get loud' for mental health. It's all part of this year's Sick of Waiting: Get Loud for Mental Health campaign. A newly formed group of mental health professionals and leaders, advocates, doctors, academics and people with lived experience is lending its voice to the campaign — and calling for changes to Canada's public drug plan system that prevents many Canadians from getting the treatment they need to get better.

The Canadians for Equitable Access to Depression Medication (CEADM) coalition — led by three of Canada's strongest advocates for mental wellness, Phil Upshall, National Executive Director of the Mood Disorders Society of Canada; Dr. Patrick Smith, CEO of the Canadian Mental Health Association; and Jeff Moat, President of Partners for Mental Health — states that under the current system, Canada's most vulnerable — the marginalized, the unemployed, veterans, seniors, single parents, Indigenous peoples — are unable to access the latest medications that could help them get better.

In forming the coalition, CEADM intends to:

• create awareness and recognition among policy-makers about the complexity of major depressive disorder and the effects of depression on Canadians' overall health;
• highlight the inequity issue for many Canadians who rely on what is a broken public drug plan approval system; and
• make better depression care a priority among policy-makers.

Improving the system will go a long way to treating what is the most significant public health issue of the 21st century.

"Canadians who live with mental illness already face the barrier of stigma as well as being debilitated by this disease," says Mr. Upshall. "But in Canada, people who rely on the provincial and territorial public drug plans either can't get access to or face considerable delays in accessing the latest medicines to treat their illness. Contrast this to people with private plans, where access to innovative medicines is far more efficient and timely."

Dr. Smith points out that this federal government has taken a bold leadership stand for mental health.  Federal Minister of Health Jane Philpott has remarked on the importance of improving accessibility to pharmaceuticals for Canadians and investing more into mental health treatment. Through her leadership and that of her fellow ministers, we are beginning to see real action taken to transform Canada's response to mental health. "Yet, despite open conversations and thoughtful discourse, despite public policy strategies and emerging philanthropic interest in mental health, people who are living with mental illness still struggle to get the care and supports they need, with ease and without prejudice," Dr. Smith adds.

Compared to other OECD countries, Canada can do better, says Laureen MacNeil, CEADM's Alberta Regional Co-Chair and Executive Director, CMHA Calgary Region: "Access to new medicines in Canada's public drug plans is lagging when compared to access in private sector drug plans, and when compared to public drug plans in other countries."

First responders like Ron Campbell, a retired RCMP officer from Alberta who has dealt with post-traumatic stress disorder and major depression, and is a member of the national coalition, appreciates the fact that his private drug plan enabled him to get the support and therapy he needed. "I'm one of the lucky ones whose private drug plan covered some of these innovative new medicines. But there are so many Canadians who aren't as fortunate as I. Access to the right medicines shouldn't be an issue for anyone. It isn't right."

The one in five Canadians who experience mental illness and the $51 billion-a-year-cost to the Canadian economy underscore the scale of the problem.

"Depression is a significant public health issue, and it's getting more problematic," says Ann Marie MacDonald, CEADM's Ontario Regional Co-Chair and Executive Director of the Mood Disorders Association of Ontario. "One in five Canadians is affected by mental illness and about 4,000 die by suicide every year. Sadly, suicide is a leading cause of death among our young people. Yet, despite the magnitude of the problem, government investment in mental health care is modest at best."

CEADM's call for change to the public drug plan system is both an equity issue and a moral issue.

"It is time for Canada to change the way we support people with mental health problems or illness.  Access to treatment should not be limited to those select few with employment benefits," adds Mr. Moat. "Changing the process that recommends drugs for reimbursement by provincial and territorial public drug plans to allow all Canadians access to the latest and best drugs to treat this complex illness is the right thing to do."

Backgrounder - Canadians for Equitable Access to Depression Medication (CEADM)

In an unprecedented move, mental health professionals and leaders, advocates, doctors, academics and people with lived experience from across the country have joined together to form a coalition to ensure equitable and sustainable access for all Canadians suffering with depression.

Through Canadians for Equitable Access to Depression Medication (CEADM), these coalition members are speaking with a common voice on behalf of Canadians who need equitable access to medication to treat their depression, regardless of their income, education or access to employment benefits.

CEADM's objectives are to:

• create awareness among policy-makers about the complexity of major depressive disorder and the effects of depression on Canadians' overall health;
• highlight the inequity/fairness issue for many Canadians who rely on a public drug plan approval system that requires fixing; and
• make depression care a priority among policy-makers.

The Issue Around Inequity and the Public Drug Plan System

At the heart of the problem, preventing vulnerable Canadians from accessing the latest medicines, are three related issues.

Number 1: Depression is complex, with 227 different combinations of symptoms. There is no 'one-size-fits-all' approach to treatment. A wide choice of therapy is critical to be able to find the best option for individual patients when it comes to treating mental illness — one that addresses not only mood but also changes in sleep patterns and appetite, as well as cognition.

Number 2: Canadians who depend on public drug coverage because of a lack of income, education or access to employment benefits are limited to a range of drugs that are available to treat depression. Currently, public drug plans only cover medications that were developed to address mood symptoms However, as we learn and understand more about depression, it is clear that a broader range of choice of medications brings with it a greater probability of success. Unfortunately, that broader range of choice of medications is not available to those on public drug plans.

Number 3: Despite the fact that innovative medications have been approved as safe and effective treatments by Health Canada, a complex multi-stage review process is preventing these medications from being approved for public drug plan coverage.

Under the current system, new drugs are submitted to a health technology assessment (HTA) agency for evaluation. While it is not the only element that is evaluated, the cost of a medication does play a significant role in the decision-making process, even though HTA evaluations are meant to be evidence-based, where clinical effectiveness and safety are also considered. The Canadian Agency for Drugs and Technologies in Health (CADTH) then releases its final recommendations to the federal and provincial/territorial governments.

Of the 21 new mental health drug submissions filed to the CADTH between 2004 and 2015:

• 76.2% were given negative recommendations for public drug plan coverage.
• 100% of the submissions for major depressive disorder received a negative recommendation — not listed for reimbursement — while of the 134 non-mental health drug submissions, 65 (48.5%) received a negative recommendation.
• The review process was considerably lengthier, at 242 days on average for mental health drugs compared to 192 days for non-mental health drugs.
• It is estimated that the direct costs of new mental health drugs on provincial, territorial and the federal Non-Insured Health Benefits (NIHB) public drug plans represents less than 1 percent of the more than $54 billion in societal costs associated with the economic burden of mental illness in Canada.

Furthermore:

• Public drug plan spending on the direct costs of new mental health drugs was less than 1% of the more than $54.6 billion associated with the total economic burden of mental illness in Canada for 205.

Members of Canadians for Equitable Access to Depression Medication to date:

Phil Upshall, National Leadership Team, Mood Disorders Society of Canada

Dr. Patrick Smith, National Leadership Team, Canadian Mental Health Association

Jeff Moat, National Leadership Team, Partners for Mental Health

Ann Marie MacDonald, Regional Ontario Co-Chair; Mood Disorders Association of Ontario

Michael Landsberg, Regional Ontario Co-Chair; #SickNotWeak

Laureen MacNeil, Regional Alberta Co-Chair; Canadian Mental Health Association, Calgary

Ron Campbell, Regional Alberta Co-Chair; person with lived experience

Dave Grauwiler, Canadian Mental Health Association, Alberta

Camille Quenneville, Canadian Mental Health Association, Ontario

Dr. Sid Kennedy, University Health Network

Pratap Chokka, Chokka Centre for Integrative Health

Bill Gaudette, formerly CMHA, Past Member, Provincial Mental Health Board (Alberta)

Brianne Moore, person with lived experience, Ontario

Jean-François Claude, person with lived experience, Ontario

SOURCE Coalition for Equitable Access to Depression Medication

Using Reality TV to Improve Men's Mental Health

Toronto psychiatrist creates bold, experimental web series Think You Can Shrink? to improve men's mental health and reduce stigma.

TORONTO, May 1, 2017 /CNW/ - A Toronto psychiatrist has developed a unique initiative to help remove the stigma associated with mental health issues among men and encourage them to seek professional help.

Dr. Thomas Ungar, an Associate Professor at the University of Toronto and Head of Psychiatry at North York General Hospital, created Think You can Shrink?, a reality TV-style web series that is generating positive results among viewers.

"Mental health issues are widely misunderstood and stigmatized among the general public," Dr. Ungar said. "I wanted to create something that goes beyond traditional health promotion. I hope that by playing with everyday pop culture like a reality show, we can help people become more comfortable with mental illness and get the help they need."

With innovation funding from the Movember Foundation, the world's leading men's health charity, and support from the North York General Hospital Foundation, Dr. Ungar created Think You Can Shrink?, a three-episode web series that focuses on intimate subjects rarely portrayed in popular culture: suicidal depression, testicular lumps, and explaining how to deal with a narcissist.

"Mental health issues are particularly acute among men, who are more likely than women to try to tough it out or struggle alone," Dr. Ungar said, noting that three out of four suicides are men and that suicide is the second-leading cause of death among men aged 15 to 29.

Employing a method used to train medical students, actors are coached to portray mental health problems.  Contestants with everyday jobs who think they are good at giving advice (a bartender, a hairdresser and a strip club owner) test their skills – both successfully and unsuccessfully.  Judges include a psychiatrist, an emergency room/family doctor and celebrity Rick Campanelli, co-host of ET Canada.

"It was a fine line to walk, trying to not be exploitive of mental health issues, but entertaining so people would watch" Dr. Ungar said.  The web series avoids the shaming factor of reality TV to show that strong male support and communication is possible, de-stigmatizing the act of reaching out for help.

A survey of people who watched the episodes concludes that the reality TV-style was successful in de-stigmatizing mental health issues and encouraging people to seek professional care.  Seventy-five per cent of viewers said they were more likely to seek help if needed, and 86% would be more comfortable supporting a friend or family member who had the same health issue as portrayed in the video, according to the study in the Journal of Technology and Behavioral Science.

About the Movember Foundation:

The Movember Foundation is the only global charity focused solely on men's health. We raise funds that deliver innovative, breakthrough research and support programs to enable men to live happier, healthier, longer lives. Awareness and fundraising activities are run year-round, with the annual Movember Campaign in November being globally recognized for its fun, disruptive approach to fundraising and getting men to take action for their health. Since Movember started in Melbourne, Australia in 2003, millions have joined the movement, raising over $759 Million and funding over 1,200 projects focused on men's mental health & suicide prevention, prostate and testicular cancer. You can help stop men dying too young at movember.com.

SOURCE Dr. Tom Ungar

Canadians Lack Access to Obesity Treatments and Support: Report Card

SOURCE The Canadian Obesity Network

Remington Pushes Green Earth Agenda for Earth Day

Downtown Markham NA’s largest LEED® Development

Downtown Markham, April 17, 2017 – The Remington Group remains fully committed to its green agenda for Downtown Markham.  This Earth Day it is planning a full program to help the community learn more about being environmentally friendly.  And it is focused particularly on its youngest residents.  Remington Group is offering a host of activities and festivities to educate the community on how to be more sustainable, learn about and visit with Canada's native animals, and test drive an EVO car.

To provide a distraction for the youngest visitors and reinforce their appreciation for time spent outdoors, they will be offer free rides on the Pride of Canada Carousel, made entirely from recycled materials.  Hidden in the colourful characters of the carousel they will find repurposed scrap metal, from all parts of the country.

"Downtown Markham is a unique development in Canada, built from the ground-up to integrate with, rather than build over, the natural environment," says Rudy Bratty, Chairman and CEO, The Remington Group. "We are determined to create a centre where the residents of Downtown Markham can live, work and play in an economically vibrant community that emphasizes sustainable development, public space, alternative energy and a higher quality of life."

Downtown Markham is the largest LEED® development in North America. Projects pursuing LEED® certification earn points across several areas that address sustainability issues. Based on the number of points achieved, a project then receives one of four LEED® rating levels: Certified, Silver, Gold and Platinum. The Remington Group only designs buildings with targets for LEED® Silver or higher.  Construction under LEED® criteria allows Remington to measure its ongoing performance, ensuring water, energy and other critical resources are managed in the most effective manner possible. 

Green initiatives used by the Remington Group:

• High density development which minimizes the environmental footprint
• Past, current and future buildings will be located close to public transit and bike paths, reducing the dependency on cars
• All high-rise communities have charging stations for electric cars
• Past, current and future buildings will have bicycle storage
• Past, current and future projects will be respectful of natural ecosystems
• Use of “green seal” certified paints are made of mostly natural, biodegradable compounds
• Use of high performance double-glazing windows ensure maximum energy efficiency
• Use of ventilators recover heated or cooled air and guarantee substantial energy savings
• Use of thermal-insulated walls minimize drafts
• Remington is working to preserve the existing Rouge River ecology while taking steps to regenerate hundreds of species of wildlife after years of farming and is committed to creating green spaces around its development projects
• Remington uses natural materials found locally to decrease the carbon footprint
• Remington’s Downtown Markham complex uses high-efficiency water recycling and heating that reduces emissions by 50%

Event Information:

Celebrate Earth Day in Downtown Markham

Date: April 22, 2017

Time: 10am to 4pm

Address: 169 Enterprise Blvd, Downtown Markham

Summer Smart Sunshine Tips to Boost Vitamin D Levels

TORONTO, Ont. (April 6, 2017) – The daylight hours are getting longer, the sun is getting stronger and summer is just around the corner. Make this the year that you optimize your vitamin D levels through effective sun exposure. Enjoy the health benefits and disease prevention from optimal vitamin D levels and learn to control your risks from sun exposure.

Vitamin D is made naturally in your body when UVB rays from the sun convert cholesterol in your skin to pre-vitamin D3. We make about 90% of our vitamin D from UVB sun exposure. UVB rays are short and only reach the earth when the sun is directly above us. We can’t make vitamin D in the winter in Canada because the sun is at too low of an angle and the UVB rays are absorbed in the atmosphere.

You make vitamin D in Canada between the months of May and October. The best time for exposure is around midday, between 10am and 2pm, when the UV index is above 3 and your shadow is shorter than your height. The further you get from noon, the lower the amount of vitamin D you’ll make. The sun’s visible light may penetrate through glass, but UVB light will not therefore you will not make vitamin D.

Full body sun exposure at non-burning levels can create between 10,000-25,000 IU of vitamin D in your skin. You can never get too much vitamin D from the sun as your skin self regulates itself, whereas ingesting vitamin D does not have the same control. In addition, vitamin D that you make from the sun lasts twice as long in your body as vitamin D taken through supplements or food.

Statistics Canada reports that Canadian vitamin D levels have dropped by 10% over the past six years. The root cause of this decrease is lower sunshine exposure. People are just not getting outside around midday in the summer and making vitamin D and when they are outside they are using sunscreen which if applied correctly prevents 95%+ of vitamin D production.

In Canada, 12 million Canadians (35%) have vitamin D blood levels below the recommendations from Health Canada. This puts these people at a higher risk for several diseases, including cardiovascular disease, cancer, osteoporosis, diabetes, multiple sclerosis, Alzheimer’s disease and many more. In fact, a study completed in 2016 reported that if Canadians increased their vitamin D levels to the recommended level of 100 nmol/L, we would save $12.5B in healthcare costs and 23,000 premature deaths annually.

A recent study reported that women who avoided the sun have twice the risk of all cause death. The authors said that “avoidance of sun exposure is a risk factor for death of a similar magnitude as smoking.”

Skin cancer is a concern and risk of sun exposure must be managed and balanced with the benefits from vitamin D and other photoproducts. Research has shown that people with higher sun exposure such as outdoor workers, who have 3-10 times the sun exposure as indoor workers, have a lower incidence of melanoma. The National Cancer Institute reports that melanoma risk is increased as a result of intermittent acute sun exposure leading to sunburn. People who are a skin type 1, with white or very pale skin colour, red or blonde hair colour and who always burn and never tan, should severely limit their sun exposure.

The Vitamin D Society offers the following tips:

• Know your own skin and skin type. Don’t burn. Never overexpose yourself.
• Acclimatize or condition your skin for sun exposure by gradually building or lengthening exposure times as your skin begins to tan to reduce your risk of burning
• Prevent burning and overexposure when required through the use of hats, clothing, shade and sunscreens
• For vitamin D get sun exposure at midday, between 10am and 2pm, when the UV index is above 3 and your shadow is shorter than your height
• Expose more skin for a shorter period of time to generate more vitamin D while reducing your risk of overexposure.

It’s important to manage the risk and enjoy the rewards of moderate sun exposure for good health. Cancer Research UK, through the Consensus Vitamin D Position Statement, offers the following recommendation: “Enjoy the sun safely while taking care not to burn, can help provide the benefits of vitamin D without unduly raising the risk of skin cancer.”

“This advice may go against what current health organizations recommend,” says Perry Holman, Executive Director of the Vitamin D Society. “They typically recommend you stay out of the sun at midday and use sunscreen when outdoors. But this would reduce your potential vitamin D production and does not consider the benefits as well as the risks of sun exposure on overall health. You need to have balance.”

About the Vitamin D Society:

The Vitamin D Society is a Canadian non-profit group organized to increase awareness of the many health conditions strongly linked to vitamin D deficiency; encourage people to be proactive in protecting their health and have their vitamin D levels tested annually; and help fund valuable vitamin D research. The Vitamin D Society recommends people achieve and maintain optimal 25(OH)D blood levels between 100 – 150 nmol/L (Can) or 40-60 ng/ml (USA).

To learn more about vitamin D, please visit www.vitamindsociety.org

Canada's Minister of Health gets a healthy dose of hope and happiness

SOURCE Saint Elizabeth Health Care

Toronto’s Beer-iest 5K Run Returns to Ontario Place

Toronto (April 10, 2017) --- More than 3,000 runners, walkers and beer lovers are expected to lace up for the second annual Famous Canadian Beer Run on Sunday, September 17, 2017. The event features a scenic 5-kilometre run through Ontario Place, followed by a Craft Beer and Food Festival for participants at the finish line. Costumed runners, cold beer and fantastic live entertainment make for a memorable run for beginners, beer lovers and seasoned racers alike!

Recently named by Toronto.com as one of Toronto’s Best Fun Runs, this beer-themed event offers participants stunning views of Lake Ontario and the city skyline as they make their way to the finish line where beer awaits. Crossing the finish line into the heart of the Craft Beer and Food Festival participants are handed a custom beer stein and are invited to sample brews from Ontario’s top craft breweries, including Beau’s All Natural, Lost Craft Beer, High Park Brewery, Great Lakes Brewery and Shawn and Ed Brewing Co. Other alcoholic beverages such as soCIALITE Vodka and Shiny Apple Cider are also on hand for non-beer drinkers.

Enjoying an afternoon relaxing and recovering from the race, the Festival features a live band and food from some of the city’s top food vendors, including Heirloom Toronto. Traditional post-run food like bagels and bananas are also on offer. Vendors such as event sponsor New Balance Toronto and the Society of Beer Drinking Ladies are on-site with running and beer-themed products available for purchase. The Famous Canadian Beer Run is an official Toronto Beer Week event.

Included in run registration is a race t-shirt, custom beer stein, beer chips good for two 8 oz. beers (or 4 samples) at the Festival and a race kit. The run is not a timed event and is open to runners and walkers of all abilities. Those who do not wish to participate in the 5K can attend the Craft Beer and Food Festival by purchasing a Festival Only pass ($25), which also includes the stein and beer chips good for two 8 oz. beers (or 4 samples). Additional beer tokens can be purchased in advance or on-site. Twenty-five “Brew Crew” runners from Toronto’s RUN-TO-BEER club dress up in costume to run alongside and cheer other runners along.

Early-bird pricing for the event is in effect until April 30^th and the first 450 registrants receive a free Run Hoppy toque. Registration is open online at www.runforbeer.ca.

Government of Canada and JDRF join forces to defeat diabetes

Building a strong partnership to accelerate clinical research on type 1 diabetes

OTTAWA, April 10, 2017 /CNW/ - David McGuinty, MP for Ottawa South, on behalf of the Honourable Jane Philpott, Minister of Health, announced today that the Government of Canada is investing in a new partnership that will help improve health outcomes and quality of care for the more than 300,000 Canadians living with type 1 diabetes, and their families.

The announcement was made at the Children's Hospital of Eastern Ontario (CHEO). Members of the All-Party Juvenile Diabetes Caucus – Pamela Goldsmith-Jones, MP for West Vancouver—Sunshine Coast—Sea to Sky Country, Sonia Sidhu, MP for Brampton South, and Filomena Tassi, MP for Hamilton West—Ancaster—Dundas – were on hand for the announcement.

The Government of Canada, through the Canadian Institutes of Health Research (CIHR), is partnering with JDRF to support clinical trials research for type 1 diabetes. Both CIHR and JDRF have committed $15M to the Partnership to Defeat Diabetes, for a total investment of $30M.

JDRF and CIHR share a vision of improved care, outcomes and treatment for Canadians living with Type 1 diabetes. The investment announced today will advance the search for a cure and ensure that research results are applied for patient care for those living with diabetes and other autoimmune diseases. This world-class collaboration also provides an opportunity to maintain Canada's leadership in diabetes research and clinical trials.

CIHR welcomes investments from important charities like JDRF. These partnerships play a key role in advancing world-class research that strengthens the health care system and improves the health of Canadians.

Quotes

"The Government of Canada recognizes the impact that type 1 diabetes has on Canadians and their families. This research will help improve the quality of life for Canadians living with type 1 diabetes and drive efforts to find a cure for this condition."
Jane Philpott
Minister of Health

"CIHR is proud to be working with JDRF to support research on type 1 diabetes. This new partnership will focus the efforts of the diabetes research community in Canada and speed the development of new and better treatments for all Canadians with diabetes. "
Dr. Philip Sherman
Scientific Director, CIHR Institute of Nutrition, Metabolism and Diabetes

"We are honoured to partner with CIHR to continue funding the best and brightest scientists in the field. This partnership will enable JDRF Canada to make significant advancements in the fight against diabetes and to positively impact the lives of the hundreds of thousands of Canadians currently living with type 1 diabetes. I am also grateful for the hard work of the All-Party Juvenile Diabetes Caucus, chaired by MP Pam Goldsmith-Jones. Pam is a strong advocate for the partnership between the Canadian Institutes of Health Research and JDRF, and for Canada's leadership in tackling diabetes."
Dave Prowten
President and CEO, JDRF Canada  

"Canada is known for its state-of-the-art type 1 diabetes research, and has played a pivotal role in ground-breaking discoveries. We are pleased to be entering into this exciting partnership with CIHR to advance global science excellence."
Derek Rapp
CEO, JDRF International 

"As a parent of a daughter who lives with type 1 diabetes, I know how challenging life is for these children and their families. Canadians are very grateful to Minister Philpott and for the constant efforts of JDRF, which have resulted in this historic investment in diabetes research."
Pamela Goldsmith-Jones, MP for West Vancouver—Sunshine Coast—Sea to Sky Country,
Chair of the All-Party Juvenile Diabetes Caucus 

Quick Facts

• Type 1 diabetes is a disease in which the pancreas does not produce insulin. When this happens, blood glucose levels rise and, over time, the high level of glucose can damage nerves, blood vessels and organs.
• An estimated 300,000 Canadians are living with type 1 diabetes. The number of people living with type 1 diabetes is increasing by 5% annually – and the greatest rise is in children under five years of age.
• CIHR and JDRF have established a $30 million partnership to fund clinical research to improve the treatment of type 1 diabetes and accelerate the search for a cure.

At the Canadian Institutes of Health Research (CIHR), we know that research has the power to change lives. As Canada's health research investment agency, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system. www.cihr-irsc.gc.ca

JDRF is the leading global organization funding type 1 diabetes research. JDRF's goal is to progressively remove the impact of type 1 diabetes from people's lives until we achieve a world without type 1 diabetes. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes. As the largest charitable supporter of type 1 diabetes research, JDRF is currently sponsoring $530 million in scientific research in 18 countries. 
www.jdrf.ca

SOURCE Canadian Institutes of Health Research